ONSHOHOCKEN, PA — Suvoda said it made significant strides in 2025 toward simplifying the clinical trial experience for patients and research sites, pointing to its merger with Greenphire, expanded product offerings, and growing use of artificial intelligence as key drivers of momentum heading into 2026.
Company leaders said the Greenphire merger marked a turning point, allowing Suvoda to address long-standing operational challenges in clinical trials through a more unified technology ecosystem designed to reduce complexity across the trial lifecycle.
Jagath Wanninayake, Suvoda’s chief executive officer, said the company spent the past year integrating teams, technologies, and capabilities while keeping patient and site needs at the center of its strategy.
A major milestone in 2025 was the launch of Suvoda’s patient app, which consolidates electronic clinical outcome assessments, patient payments, visit scheduling, and reminders into a single interface accessible on participants’ personal devices. The company said the app is intended to improve patient engagement while reducing administrative demands on trial sites.
Suvoda also expanded its use of artificial intelligence with the deployment of Sofia, an AI assistant currently embedded within Suvoda IRT. The tool allows study teams to retrieve information and answers through natural-language queries, replacing multi-step system navigation. The company said Sofia was built with privacy safeguards and role-based controls to support decision-making without compromising data security or study integrity.
The company’s innovation efforts earned external recognition in 2025, including the issuance of a new patent related to its platform architecture, bringing Suvoda’s total patent count to five. Everest Group also named Suvoda a Leader in its RTSM PEAK Matrix assessment. Additional product enhancements rolled out during the year focused on improving data quality, transparency, and usability for sponsors and sites.
Looking ahead, Suvoda said it expects continued growth in 2026 as pharmaceutical sponsors and contract research organizations increasingly seek unified platforms that streamline trial operations while delivering a better experience for patients.
Company executives said the integration work completed in 2025 has positioned Suvoda to support a broader range of clinical trial needs as demand rises for more connected, patient-centered trial technology.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.